Fig 11.
Infection of C57BL/6 Ifngr−/− mice at 7.0 log10 PFU/mouse dose with VACV-WR, VACV-IHD, VACV-Lis, VACV-NYCBH, TNX-801, and PBS via intranasal (IN) route (A). Following infection, mice were monitored for disease score (B), body temperature (C), weight loss (D), and survival (E). The target dose for each virus was verified via the plaque assay, and values are provided (A). p-values comparing VACV strains to TNX-801 and mock groups are provided in each graph.
